- Home
- VERV vs XERS Comparison
VERV vs XERS Comparison
Compare VERV & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- XERS
- Stock Information
- Founded
- VERV 2018
- XERS 2005
- Country
- VERV United States
- XERS United States
- Employees
- VERV N/A
- XERS N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- VERV Health Care
- XERS Health Care
- Exchange
- VERV Nasdaq
- XERS Nasdaq
- Market Cap
- VERV 475.0M
- XERS 509.9M
- IPO Year
- VERV 2021
- XERS 2018
- Fundamental
- Price
- VERV $5.50
- XERS $3.40
- Analyst Decision
- VERV Strong Buy
- XERS Buy
- Analyst Count
- VERV 4
- XERS 3
- Target Price
- VERV $25.75
- XERS $4.87
- AVG Volume (30 Days)
- VERV 1.6M
- XERS 1.6M
- Earning Date
- VERV 11-05-2024
- XERS 11-08-2024
- Dividend Yield
- VERV N/A
- XERS N/A
- EPS Growth
- VERV N/A
- XERS N/A
- EPS
- VERV N/A
- XERS N/A
- Revenue
- VERV $24,396,000.00
- XERS $187,361,000.00
- Revenue This Year
- VERV $97.47
- XERS $23.48
- Revenue Next Year
- VERV N/A
- XERS $18.69
- P/E Ratio
- VERV N/A
- XERS N/A
- Revenue Growth
- VERV 219.91
- XERS 22.72
- 52 Week Low
- VERV $4.31
- XERS $1.69
- 52 Week High
- VERV $19.34
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- VERV 44.33
- XERS 50.76
- Support Level
- VERV $5.19
- XERS $3.26
- Resistance Level
- VERV $7.40
- XERS $3.63
- Average True Range (ATR)
- VERV 0.65
- XERS 0.17
- MACD
- VERV -0.12
- XERS -0.02
- Stochastic Oscillator
- VERV 7.88
- XERS 15.57
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.